This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Henderson GS , van Diest PJ , Burger H , Russo J , Raman V
Expression pattern of a homeotic gene, HOXA5, in normal breast and in breast tumors
Cellular Oncology. 2006 ;28(5-6) :305-313
AbstractIntroduction: Homeotic (HOX) gene products are now known to be functionally associated with breast cancer biogenesis. Recent evidence has indicated that HOXA5 regulates both p53 and progesterone receptor expression levels in breast cancer cells. In addition, HOXA5 has been shown to interact and regulate the activity of another protein referred to as Twist. As homeotic genes play a pivotal role in development, we sought to decipher the expression pattern in both normal breast tissues and in breast carcinomas. Methods: RT-PCR and immunohistochemistry were performed, to assay the levels of HOXA5 expression, on a panel of normal breast tissue and its corresponding primary breast tumors. Results and Conclusions: We show that HOXA5 expression was maintained at stable levels at different reproductive stages of a woman's life, except during lactation. This evidence indicates that HOXA5 may play a role in maintaining the differentiated state within the breast epithelium. However, nearly 70% of all breast carcinomas had decreased HOXA5 protein levels as compared to normal breast tissues. In addition, we demonstrate that HOXA5 protein expression levels in breast carcinomas inversely co-relates with Epidermal Growth Factor Receptor (EGFR) expression. Furthermore, we found that the survival rate amongst the different low levels of HOXA5 expressing breast tumors was not significant, indicative of an early tumorigenesis process in the absence of innate levels of HOXA5 in normal breast cells.
NotesISI Document Delivery No.: 135GX Times Cited: 0 Cited Reference Count: 42 Cited References: ABATESHEN C, 2002, NAT REV CANCER, V2, P777 ABRAMOVICH C, 2005, CURR OPIN HEMATOL, V12, P210 AKIN ZN, 2005, CELL MOL NEUROBIOL, V25, P697 ANBAZHAGAN R, 1997, EUR J CANCER, V33, P635 BIFFO S, 1992, LIVER, V12, P230 BURGER H, 2000, PATHOLOGE, V21, P375 CANTILE M, 2003, EUR J CANCER, V39, P257 CARPENTER G, 2003, CURR OPIN CELL BIOL, V15, P143 CHEN HX, 2004, MOL CELL BIOL, V24, P924 CILLO C, 1992, INT J CANCER, V51, P892 COHEN BD, 1998, BIOCH SOC S, V63, P199 COHEN S, 1982, P NATL ACAD SCI USA, V79, P6237 DAVIS AP, 1996, DEVELOPMENT, V122, P1175 DEJONG JS, 1998, J PATHOL, V184, P53 DELACRUZ CC, 1999, DEV BIOL, V216, P595 DESCHAMPS J, 1992, CRIT REV ONCOGENESIS, V3, P117 DEVITA G, 1993, EUR J CANCER, V29, P887 EKLUND EA, 2006, CURR OPIN HEMATOL, V13, P67 GOODMAN FR, 2003, LANCET, V362, P651 GREER JM, 2002, NEURON, V33, P23 HSU K, 2003, CANCER CELL, V4, P81 KAPPEN C, 2000, AM J HEMATOL, V65, P111 LACELLE PT, 2001, J BIOL CHEM, V276, P32844 LO HW, 2005, CANCER RES, V65, P338 MARK M, 1997, PEDIATR RES, V42, P421 MICHALCZYK A, 2001, DIFFERENTIATION, V67, P41 MORGAN R, 2006, TRENDS GENET, V22, P67 MORTLOCK DP, 1996, NAT GENET, V13, P284 MORTLOCK DP, 1997, NAT GENET, V15, P179 PACKEISEN J, 2002, J CLIN PATHOL, V55, P613 PACKEISEN J, 2003, MOL PATHOL, V56, P198 PEARSON JC, 2005, NAT REV GENET, V6, P893 RAMAN V, 2000, NATURE, V405, P974 REILLY CE, 2002, J NEUROL, V249, P499 RUSSO J, 2001, MICROSC RES TECHNIQ, V52, P204 SHIMAMOTO T, 1998, INT J HEMATOL, V67, P339 STASINOPOULOS IA, 2005, J BIOL CHEM, V280, P2294 SVINGEN T, 2003, CANCER BIOL THER, V2, P518 TIBERIO C, 1994, INT J CANCER, V58, P608 TOURNIERLASSERVE E, 1989, MOL CELL BIOL, V9, P2273 VERAKSA A, 2000, MOL GENET METAB, V69, P85 WAHBA GM, 2001, DEV BIOL, V231, P87 Henderson, Gregory S. van Diest, Paul J. Burger, Horst Russo, Jose Raman, Venu